Danaher (DHR)
continues to show why it’s one of the more highly-regarded
conglomerates; second quarter revenue and margin leverage will most
likely be on the good side of average in what is shaping up as a pretty
good quarter for multi-industrials. In particular, Danaher’s pivot
toward life sciences and healthcare seems like a strong move that will
not only drive above-average growth but also above-average margins and
below-average cyclicality.
Danaher shares have been
pretty lackluster over the past three months, though they continue to
stack well on a year-to-date and 12-month basis. These shares are still
not what I would call cheap, but waiting for a good entry point with
this stock often takes time and patience – those opportunities come, but
they don’t come often and investors have to make peace with the risk of
being on the outside of a pretty well-run company in the meantime.
Click here for more:
Life Sciences Performing Well For Danaher
No comments:
Post a Comment